April 13, 2021: Novaliq GmbH

BAUSCH + LOMB ANNOUNCES STATISTICALLY SIGNIFICANT TOPLINE RESULTS FROM THE FIRST PHASE 3 TRIAL OF NOV03 (PERFLUOROHEXYLOCTANE) IN DRY EYE DISEASE ASSOCIATED WITH MEIBOMIAN GLAND DYSFUNCTION

All Primary and Secondary Endpoints Were Achieved

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced statistically significant topline data from the first Phase 3 trial (GOBI trial) evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD).

Please read the whole article here

News 2021, Novaliq GmbH

April 12, 2021: Cosmo Pharmaceuticals NV

Cosmo announces FDA approval of GI Genius™ intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy

Cosmo Pharmaceuticals NV today announced the FDA approval of GI Genius™ intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy.

The GI Genius module FDA approval marks a pivotal milestone for Cosmo after more than 10 years of research and investments focused to generate disruptive innovations in the field of colon’s disease and optimization of the colonoscopy procedure. The development of GI Genius intelligent endoscopy module has been possible thanks to the leadership position of Cosmo, its unique proprietary library of high-definition loss-less videos of colonoscopies and its proprietary software and algorithms. The device is the first of its kind to obtain the FDA approval through the De Novo application. The device operates in real time to assist the endoscopist in the detection of lesions, is very simple to use and is compatible with all endoscopes. Cosmo is the sole manufacturer. Medtronic is the exclusive world-wide distributor.

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2021

March 31, 2021: Joimax GmbH

joimax® Celebrates 20th Anniversary, Expands Education Program

Founded 2001 in Germany, joimax®, the leading manufacturer of medical devices for endoscopic minimally invasive spine surgery, celebrates its 20th anniversary this year. In tandem with this milestone, the company expanded their educational program, ESPINEA®, furthering their global reach.

Despite COVID-19, ESPINEA® (Endoscopic Spine Academy) training programs, which are held in cooperation with the Royal College of Surgeons Edinburgh (RCSEd) and joimax®, were conducted all over the world in 2020, and continue to roll out in 2021. Due to travel restrictions, the programs were adapted to webinars, and remote support and training, totaling 60 sessions last year. By pivoting to online learning, approximately 3000 surgeons were reached in 2020, and 700 surgeons so far in 2021.

Please read the whole article here

Joimax GmbH, News 2021

March 31, 2021: AC Immune SA

AC Immune Hosts Investor Webinar Highlighting the Power of its MorphomerTM Platform to Enable Precision Medicine for Neurodegenerative Disease

Clinically validated platform accelerates the discovery and development of first-in-class small molecule therapeutics in parallel with companion diagnostics

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will host an investor webinar today to discuss the unique benefits of the Company’s innovative MorphomerTM technology platform, which generates first-in-class therapeutic and diagnostic candidates to power AC Immune’s precision medicine approach for neurodegenerative diseases. The live webinar begins at 10am ET and can be accessed here.

Please read the whole article here

AC Immune SA, News 2021

March 31, 2021: Heidelberg Pharma AG

Heidelberg Pharma to Present New Data on its Proprietary ATAC Technology Platform at the AACR Annual Meeting 2021

Heidelberg Pharma AG announced today that it will present preclinical data on its novel ATAC candidates HDP-102 and HDP-103 as well as data on synergistic effects of ATACs with checkpoint inhibitors at the American Association for Cancer Research (AACR) 2021 Annual Meeting. The meeting will be held in a virtual format from April 10 – 15, 2021.

Please read the whole article here

Heidelberg Pharma AG, News 2021

March 30, 2021: CureVac AG

Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV

Celonic is prepared to manufacture more than 100 million doses of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV, per year
More than 50 million doses are expected to be produced before the end of 2021
The mRNA-based vaccine will be manufactured at Celonic’s state-of-the-art facility in Heidelberg, Germany

CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) and Celonic Group, a premium biopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of Advanced Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed bio-therapeutics, today announced their partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.

Please read the whole article here

CureVac AG, News 2021

March 30, 2021: Immatics Biotechnologies GmbH

Immatics Announces Full Year 2020 Financial Results and Corporate Update

Phase 1a data update from clinical ACTengine® programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients
Enrollment across clinical ACTengine® IMA200 trial series continues to scale up
Cash and cash equivalents as well as other financial assets of $285 million1 (€232 million) as of December 31, 2020 provide cash reach into 2023

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2020.

Please read the whole article here

Immatics Biotechnologies GmbH, News 2021

March 26, 2021: AC Immune SA

AC Immune to Host Webinar Highlighting its Innovative MorphomerTM Technology Platform and Pipeline

Therapeutic and diagnostic Morphomers™ enable AC Immune’s unique precision medicine approach for neurodegenerative diseases

Webinar will take place on Wednesday, March 31, 2021 at 10:00 AM ET

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a corporate update webinar on Wednesday, March 31st at 10:00 AM ET until 11:30 AM ET.

Please read the whole article here

AC Immune SA, News 2021

March 26, 2021: Cosmo Pharmaceuticals NV

Cosmo Full-Year Report 2020: Cosmo returns to operating profit

Cosmo Pharmaceuticals N.V. reports Full-Year results for the year ended 31 December 2020.

In 2020, Cosmo received European approval for Methylene Blue MMX®, received FDA approval for BYFAVO™, continued to execute its equity for product strategy and has returned to operating profit. The Company is very well positioned with €212.9 million in cash and significant equity stakes in other companies.

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2021

March 25, 2021: Heidelberg Pharma AG

Heidelberg Pharma announces financial figures for fiscal year 2020 and provides business update

Application to initiate clinical trial of HDP-101 green-lighted by the FDA in February 2021
Two more development candidates added to the pipeline
Capital increase implemented and shareholder loans granted
Financial figures in line with planning, with increased income and higher spending on R&D
New financing commitment for up to EUR 30 million obtained from main shareholder dievini
Conference call to be held on 25 March 2021 at 3:00 p.m. CET

Heidelberg Pharma AG today published its financial results and annual report for fiscal year 2020 (01 December 2019 – 30 November 2020) and its outlook for 2021.

Please read the whole article here

Heidelberg Pharma AG, News 2021